242 related articles for article (PubMed ID: 32713127)
1. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?
Criado PR; Pagliari C; Criado RFJ; Marques GF; Belda W
Dermatol Ther; 2020 Nov; 33(6):e14068. PubMed ID: 32713127
[TBL] [Abstract][Full Text] [Related]
2. Comparable actions of omalizumab on mast cells and basophils.
Serrano-Candelas E; Martinez-Aranguren R; Valero A; Bartra J; Gastaminza G; Goikoetxea MJ; Martín M; Ferrer M
Clin Exp Allergy; 2016 Jan; 46(1):92-102. PubMed ID: 26509363
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
4. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
6. Justification for IgE as a therapeutic target in chronic spontaneous urticaria.
Sánchez-Borges M; Capriles-Hulet A; Caballero-Fonseca F; González-Aveledo L
Eur Ann Allergy Clin Immunol; 2017 Jul; 49(4):148-153. PubMed ID: 28752717
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema.
Altman K; Chang C
Clin Rev Allergy Immunol; 2013 Aug; 45(1):47-62. PubMed ID: 22674016
[TBL] [Abstract][Full Text] [Related]
9. Case report: SARS-CoV-2-induced urticaria or just a concomitance?
Fida M; Mala R; Pupo L; Dibra A; Nasto K
Dermatol Ther; 2020 Nov; 33(6):e14250. PubMed ID: 32860461
[TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
[TBL] [Abstract][Full Text] [Related]
12. Anti-IgE monoclonal antibodies as potential treatment in COVID-19.
Farmani AR; Mahdavinezhad F; Moslemi R; Mehrabi Z; Noori A; Kouhestani M; Noroozi Z; Ai J; Rezaei N
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):259-264. PubMed ID: 34018464
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
Borges RC; Hohmann MS; Borghi SM
Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
[TBL] [Abstract][Full Text] [Related]
14. Advances in anti-IgE therapy.
Yalcin AD
Biomed Res Int; 2015; 2015():317465. PubMed ID: 26075226
[TBL] [Abstract][Full Text] [Related]
15. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria.
Poddighe D; Vangelista L
Cell Immunol; 2020 Dec; 358():104215. PubMed ID: 33137647
[TBL] [Abstract][Full Text] [Related]
16. [Pathophysiology of urticaria].
Nosbaum A; Augey F; Nicolas JF; Bérard F
Ann Dermatol Venereol; 2014 Nov; 141 Suppl 3():S559-64. PubMed ID: 25539676
[TBL] [Abstract][Full Text] [Related]
17. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
Gomez G
Front Immunol; 2019; 10():175. PubMed ID: 30792720
[TBL] [Abstract][Full Text] [Related]
18. How Infection and Vaccination Are Linked to Acute and Chronic Urticaria: A Special Focus on COVID-19.
Kocatürk E; Muñoz M; Elieh-Ali-Komi D; Criado PR; Peter J; Kolkhir P; Can P; Wedi B; Rudenko M; Gotua M; Ensina LF; Grattan C; Maurer M
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515272
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic uses of omalizumabtitle.
Chia JC; Mydlarski PR
J Dermatolog Treat; 2017 Jun; 28(4):332-337. PubMed ID: 27759482
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab may protect allergic patients against COVID-19: A systematic review.
Ghiglioni DG; Cozzi EL; Castagnoli R; Bruschi G; Maffeis L; Marchisio PG; Marseglia GL; Licari A
World Allergy Organ J; 2023 Feb; 16(2):100741. PubMed ID: 36644451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
